Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.

@article{Perrett2015ImmuneRT,
  title={Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.},
  author={Kirsten P. Perrett and Jodie Mcvernon and Peter C. Richmond and Helen Siobhan Marshall and Michael D. Nissen and Allison Carnegie August and Sandra Percell and Daniela Toneatto and Terence M Nolan},
  journal={Vaccine},
  year={2015},
  volume={33 39},
  pages={5217-24}
}
BACKGROUND For decades, a broadly effective vaccine against serogroup B Neisseria meningitidis (MenB) has remained elusive. Recently, a four-component recombinant vaccine (4CMenB) has been developed and is now approved in Europe, Canada, Australia and some Latin American countries. This phase III, randomized study evaluated the lot consistency, early immune responses and the safety profile of 4CMenB in 11 to 17-year-old adolescents in Australia and Canada (NCT01423084). METHODS In total, 344… CONTINUE READING
7 Citations
37 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Invasive meningococcal disease (laboratory reports in England): 2013/2014 annual data by epidemiological year; 2013/2014

  • PH England
  • 2014

in healthy adults

  • PC Richmond, HS Marshall, Nissen, Q Jiang, KU Jansen, M Garces-Sanchez
  • 2013

strain coverage

  • HS Marshall, PC Richmond, Nissen, A Wouters, J Baber, Q Jiang
  • 2013

Similar Papers

Loading similar papers…